» Articles » PMID: 28196836

Label-Free Dynamic Mass Redistribution Reveals Low-Density, Prosurvival -Adrenergic Receptors in Human SW480 Colon Carcinoma Cells

Overview
Specialty Pharmacology
Date 2017 Feb 16
PMID 28196836
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Small molecules that target the adrenergic family of G protein-coupled receptors (GPCRs) show promising therapeutic efficacy for the treatment of various cancers. In this study, we report that human colon cancer cell line SW480 expresses low-density functional -adrenergic receptors (ARs) as revealed by label-free dynamic mass redistribution (DMR) signaling technology and confirmed by quantitative reverse-transcriptase polymerase chain reaction analysis. Remarkably, although endogenous -ARs are not detectable via either [H]-prazosin-binding analysis or phosphoinositol hydrolysis assays, their activation leads to robust DMR and enhanced cell viability. We provide pharmacological evidence that stimulation of -ARs enhances SW480 cell viability without affecting proliferation, whereas stimulating -ARs diminishes both viability and proliferation of SW480 cells. Our study illustrates the power of label-free DMR technology for identifying and characterizing low-density GPCRs in cells and suggests that drugs targeting both - and -ARs may represent valuable small-molecule therapeutics for the treatment of colon cancer.

Citing Articles

Understanding the role of nerves in head and neck cancers - a review.

Rutkowski K, Gola M, Godlewski J, Starzynska A, Marvaso G, Mastroleo F Oncol Rev. 2025; 18:1514004.

PMID: 39906323 PMC: 11791411. DOI: 10.3389/or.2024.1514004.


β-Adrenoceptor Activation Favor Acquisition of Tumorigenic Properties in Non-Tumorigenic MCF-10A Breast Epithelial Cells.

Silva D, Quintas C, Goncalves J, Fresco P Cells. 2024; 13(3.

PMID: 38334654 PMC: 10854540. DOI: 10.3390/cells13030262.


Development of a Novel SNAP-Epitope Tag/Near-Infrared Imaging Assay to Quantify G Protein-Coupled Receptor Degradation in Human Cells.

Lee K, Navaluna E, Marsh N, Janezic E, Hague C SLAS Discov. 2021; 26(4):570-578.

PMID: 33402011 PMC: 9246501. DOI: 10.1177/2472555220979793.


N-glycosylation of α-adrenergic receptor N-terminal domain is required for correct trafficking, function, and biogenesis.

Janezic E, Lauer S, Williams R, Chungyoun M, Lee K, Navaluna E Sci Rep. 2020; 10(1):7209.

PMID: 32350295 PMC: 7190626. DOI: 10.1038/s41598-020-64102-4.

References
1.
Cole S, Sood A . Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2011; 18(5):1201-6. PMC: 3294063. DOI: 10.1158/1078-0432.CCR-11-0641. View

2.
Lefkowitz R, Rockman H, Koch W . Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000; 101(14):1634-7. DOI: 10.1161/01.cir.101.14.1634. View

3.
Martin D, Lluel P, Guillot E, Coste A, Jammes D, Angel I . Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997; 282(1):228-35. View

4.
Wagner J, Endoh M, Reinhardt D . Stimulation by phenylephrine of adrenergic alpha- and beta-receptors in the isolated perfused rabbit heart. Naunyn Schmiedebergs Arch Pharmacol. 1974; 282(3):307-10. DOI: 10.1007/BF00501238. View

5.
Liu H, Enyeart J, Enyeart J . Potent inhibition of native TREK-1 K+ channels by selected dihydropyridine Ca2+ channel antagonists. J Pharmacol Exp Ther. 2007; 323(1):39-48. DOI: 10.1124/jpet.107.125245. View